CGM Cuts HbA1c in Non-Insulin Type 2 Diabetes, Major Meta-Analysis Confirms

Continuous glucose monitoring has long been considered standard care for insulin-treated diabetes, but its role in the much larger population of people with type 2 diabetes (T2DM) managed without insulin has remained debated—partly because earlier trials predominantly enrolled insulin users. This paper addresses that gap with both a comprehensive narrative review and a focused systematic meta-analysis restricted to noninsulin-treated T2DM.

The authors—a Canadian expert panel of endocrinologists and a family physician—searched PubMed, Embase, and the Cochrane Library for studies using CGM or flash glucose monitoring in T2DM. The narrative component reviewed observational studies and RCTs in mixed (insulin and noninsulin) T2DM populations, while the meta-analysis was restricted to RCTs enrolling only noninsulin-treated participants comparing CGM to blood glucose monitoring (BGM) or usual care.

Eight RCTs met inclusion criteria for the meta-analysis, enrolling 541 total participants (297 in CGM groups). Results were strikingly consistent: CGM reduced HbA1c by a weighted mean difference of −0.37% (95% CI −0.49 to −0.24, p<0.00001), increased time-in-range by 8.84 percentage points (95% CI 4.62–13.06, p<0.0001), and reduced time-above-range by 8.14 percentage points (95% CI −12.66 to −3.63, p=0.0004). Importantly, heterogeneity was zero (I²=0%) across all three primary outcomes, and subgroup analyses by CGM type (intermittently scanned vs. real-time) showed no significant differences, suggesting both modalities confer similar benefit.

The narrative review added important context: observational studies and mixed-population RCTs broadly corroborated the glycemic benefits and also demonstrated improvements in patient experience, motivation for lifestyle modification, and reductions in healthcare resource utilization. Cost-effectiveness analyses reviewed were generally favorable. The paper also catalogues available CGM device types—intermittently scanned (isCGM), real-time (rtCGM), professional/retrospective, and over-the-counter—with their technical specifications, helping clinicians match device choice to patient needs.

The authors note that the aggregated sample sizes remain modest and trial durations relatively short, and that most evidence comes from specialized centers. Nonetheless, the consistency of benefit across device types, study designs, and populations strengthens the case for broader CGM adoption in noninsulin-treated T2DM, a population that represents the majority of people living with T2DM worldwide.